Study Links Increased Risk of Mental Disorders with Childhood Infections

By |2018-12-06T11:40:55+00:00December 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Furthering the role of immune system disorders in the development of mental disorders, recent research links infections that children contract during their childhood with increased risk of mental disorders during childhood and adolescence. The first study of its kind shows that high temperatures, sore throats and infections during childhood can [...]

Cassipa Approved by FDA for Opioid Dependence

By |2018-09-12T15:28:07+00:00September 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A new dosage strength of buprenorphine and naloxone sublingual film was approved recently by the Food and Drug Administration. Cassipa sublingual film, made by Teva Pharmaceuticals, is a 16 mg/4 mg dosage of buprenorphine and naloxone for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual film also is [...]

Seven-Year Analysis on Benzodiazepine Prescribing for Children, Adolescents, and Young Adults Showed Marked Increase

By |2018-08-09T08:01:59+00:00August 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Conclusions The overall increase in prevalence rates of BZD dispensations during the study period and the unexpectedly high proportion of individuals who were prescribed a BZD on a long-term basis at a young age indicate a lack of congruence with international and national guidelines. These findings highlight the need for [...]

Alzheimer’s Agent, BAN2401, Shows Promise; Trial Design Hits Snag

By |2018-08-02T07:56:18+00:00August 2nd, 2018|Brief Bulletins from the Field, We Know Psychiatry|

A monoclonal antibody,BAN2401, that targets soluble amyloid-beta oligomers, slowed cognitive decline by up to 47% while clearing brain amyloid in 81% of patients with mild cognitive impairment and very mild Alzheimer’s disease, according to phase 2 study results. A joint venture with Esai and Biogen, BAN2401, is among the most promising [...]

Bipolar Medication, Lamictal, Linked with Serious Immune System Reaction

By |2018-06-29T07:28:14+00:00June 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response, known as hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled immune response and can present as a persistent fever greater than 101° F. [...]

Effects of a depression-focused internet intervention in slot machine gamblers: A randomized controlled trial

By |2018-06-08T16:28:40+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only a small fraction of problematic and pathological gamblers seek professional help. The existing treatment gap could be narrowed by providing [...]

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, Trial Shows, but Decline of Clinical Symptoms Still a Question

By |2018-06-08T08:10:58+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called [...]

Esketamine nasal spray prevails in phase 3 trials

By |2018-06-06T07:29:40+00:00June 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

MIAMI — The combination of an esketamine nasal spray and an oral antidepressant may provide additional benefits for patients with treatment-resistant major depressive disorder, new research suggested. Two posters at a meeting of the American Society of Clinical Psychopharmacology, formerly known as the New Clinical Drug Evaluation Unit meeting, presented [...]

MDMA-Assisted Psychotherapy Improves PTSD

By |2018-06-05T15:12:24+00:00June 5th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies show. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2018 annual meeting. The pooled data from the [...]